TABLE 1.
Phenotypic features stratified by the 3 patient cohorts
|
T (n = 10) |
TS (n = 19) |
TSN (n = 14) |
p‐value | |
|---|---|---|---|---|
|
Leukocytes G/L; median (range) Evaluable = 43 |
5.9 (3.1–98) | 8.4 (2.9–55.1) | 34.0 (7.8–107.4) | .002 |
|
Hemoglobin g/dl; median (range) Evaluable = 43 |
11.8 (6.5–14.4) | 11.7 (8.4–14.3) | 11.0 (7.0–13.8) | .547 |
|
Platelets G/L; median (range) Evaluable = 43 |
108 (29–507) | 102 (7–345) | 92 (16–288) | .652 |
|
PB blasts %; median (range) Evaluable = 39 |
0 (0–3) | 0 (0–0) | 0 (0–57) | .006 |
|
LDH U/L; median (range) Evaluable = 27 |
181 (167–351) | 238 (68–672) | 348 (204–644) | .008 |
Abbreviations: T, CMML patients who had TET2 mutations alone; TS, CMML patients who had only TET2/SRSF2 comutations; TSN, CMML patients who had NRAS mutations in addition to TET2/SRSF2 comutations.